An article by Jay Levine was published as the AHLA Member Briefing to the Antitrust and Life Sciences Practice Groups on December 13, 2012. The briefing, “Supreme Court Grants Cert in Pharmaceutical ‘Reverse Payment’ Case,” discussed the Federal Trade Commission case to be heard by the U.S. Supreme Court. In Federal Trade Comm’n v. Watson Pharmaceuticals, the Court is being asked to decide whether certain settlement agreements in cases where brand-name pharmaceutical manufacturers sue their general counterparts for patent infringement violate antitrust laws. Levine practices in the firm’s Washington, D.C. office and focuses his practice on complex litigation, particularly antitrust and consumer protection matters.
Click to read the reprint.